Literature DB >> 20113322

Quality of life after esophagectomy and endoscopic therapy for Barrett's esophagus with dysplasia.

D Schembre1, A Arai, S Levy, M Farrell-Ross, D Low.   

Abstract

Esophagectomy (EG) and endoscopic therapy (ET) can eradicate Barrett's esophagus with early neoplasia. Their relative effect on quality of life is unknown. The 36-item Short Form Health Survey (SF-36) and Gastrointestinal Quality of Life Index (GIQLI) questionnaires were sent to all patients who underwent either EG or ET at our institution over the last 9 years. Groups were stratified by age and American Society of Anesthesia (ASA) class. Surveys were sent to 77 patients and completed by 14 EG (50%) and by 28 ET patients (57%). The average time between treatment and survey was 4 years in the ET group and 5 years in the EG group. There were no significant differences in SF-36 scores between EG and ET patients except for superior physical functioning among EG patients 65 and older QOL scores among EG and ET groups were not significantly different than sex age-matched controls. GIQLI scores were similar between ET and EG patients of all ages (P= 0.60). GIQLI scores were higher among younger ET patients than young EG patients (P= 0.049). GIQLI scores also tended to be higher among ASA 1 and 2 ET patients than ASA 1 and 2 EG patients, but this did not reach statistical significance (P= 0.09). EG and ET for early Barrett's neoplasia appear to have similar impact on QOL 1 year or more after treatment compared with age-matched controls. Negative QOL impact appears to be greater for younger patients undergoing EG than for ET.

Entities:  

Mesh:

Year:  2010        PMID: 20113322     DOI: 10.1111/j.1442-2050.2009.01042.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  7 in total

1.  Quality of life following radiofrequency ablation of dysplastic Barrett's esophagus.

Authors:  N J Shaheen; A F Peery; R H Hawes; R I Rothstein; S J Spechler; J A Galanko; M Campbell; C Carr; B Fowler; J Walsh; A A Siddiqui; A Infantolino; H C Wolfsen
Journal:  Endoscopy       Date:  2010-09-30       Impact factor: 10.093

Review 2.  Systematic review reveals limitations of studies evaluating health-related quality of life after potentially curative treatment for esophageal cancer.

Authors:  Marc Jacobs; Rhiannon C Macefield; Jane M Blazeby; Ida J Korfage; Mark I van Berge Henegouwen; Hanneke C J M de Haes; Ellen M Smets; Mirjam A G Sprangers
Journal:  Qual Life Res       Date:  2012-10-20       Impact factor: 4.147

3.  Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus.

Authors:  Cathy Bennett; Susi Green; John DeCaestecker; Max Almond; Hugh Barr; Pradeep Bhandari; Krish Ragunath; Rajvinder Singh; Janusz Jankowski
Journal:  Cochrane Database Syst Rev       Date:  2020-05-22

Review 4.  How are we measuring health-related quality of life in patients with a Barrett Esophagus? A systematic review on patient-reported outcome measurements.

Authors:  Mirjam C M van der Ende-van Loon; A Stoker; P T Nieuwkerk; W L Curvers; E J Schoon
Journal:  Qual Life Res       Date:  2021-11-08       Impact factor: 3.440

5.  Comparison of Long-Term Survival Between cT1N0 Stage Esophageal Cancer Patients Receiving Endoscopic Dissection and Esophagectomy: A Meta-Analysis.

Authors:  Wei Lu; Peng Li; Wu Wen; Yi Jian
Journal:  Front Surg       Date:  2022-05-06

Review 6.  Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs).

Authors:  Rhiannon C Macefield; Marc Jacobs; Ida J Korfage; Joanna Nicklin; Robert N Whistance; Sara T Brookes; Mirjam A G Sprangers; Jane M Blazeby
Journal:  Trials       Date:  2014-02-05       Impact factor: 2.279

7.  Comparative quantitative survey of patient experience in Barrett's oesophagus and other gastrointestinal disorders.

Authors:  James Britton; Paraskevi Taxiarchi; Glen Martin; Robert Willert; Maria Horne; Shaheen Hamdy; John McLaughlin; Yeng Ang
Journal:  BMJ Open Gastroenterol       Date:  2020-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.